

CLAIMS

1. A method of depleting a population of CD45+ cells in a human patient having an autoimmune disease, the method comprising administering to the patient having the autoimmune disease an effective
5 amount of an antibody-drug conjugate (ADC) comprising an anti-CD45 antibody, or antigen binding portion thereof, conjugated to a cytotoxin via a linker.
2. A method of conditioning a human patient having an autoimmune disease for receiving a hematopoietic stem cell (HSC) transplant, the method comprising administering to the human patient having
10 the autoimmune disease an antibody-drug conjugate (ADC) comprising an anti-CD45 antibody, or antigen binding portion thereof, conjugated to a cytotoxin via a linker.
3. The method of claim 1 or 2, wherein the autoimmune disease is an inflammatory arthritis (for example, rheumatoid arthritis), autoimmune encephalitis, scleroderma, multiple sclerosis, type 1 diabetes, or
15 systemic sclerosis.
4. The method of any one of claims 1-3, further comprising administering a transplant comprising hematopoietic stem cells (HSCs) to the patient.
- 20 5. The method of claim 4, wherein the HSC transplant is an autologous HSC transplant (autoHSCT).
6. The method of claim 4 or 5, wherein the anti-CD45 ADC is administered to the patient about three days prior to the patient receiving the transplant comprising HSCs
- 25 7. The method of any one of claim 4-6, wherein the HSC transplant is administered to the patient after the anti-CD45 ADC has substantially cleared from the blood of the human patient.
8. A method of treating a patient having scleroderma or multiple sclerosis, said method comprising administering an anti-CD45 antibody drug conjugate (ADC) to the patient having scGVHD, such that the
30 scGVHD is treated, wherein the anti-CD45 ADC comprises an anti-CD45 antibody, or fragment thereof, conjugated to a cytotoxin via a linker.
9. The method of any one of the preceding claims, wherein the anti-CD45 ADC is administered to the patient as a single dose or as a fractionated dose.
35
10. The method of any one of the preceding claims, wherein the patient does not require treatment for the autoimmune disease following transplantation.

- 40 11. The method of any one of claim 1-10, wherein the patient has multiple sclerosis, and wherein the patient does not require treatment with natalizumab, dimethyl fumarate, or monomethyl fumarate following transplantation.
- 45 12. The method of any one of claim 1-10, wherein the patient has arthritis, and wherein the patient does not require treatment with a TNF inhibitor following transplantation.
13. The method of claim 12, wherein the TNF inhibitor is an anti-TNF α antibody.
- 50 14. The method of any one of claims 1-13, wherein the patient enters remission for at least 1 year, at least 2 years, or at least 5 years following transplantation.
- 55 15. The method of claim 14, wherein the remission is clinical remission, biochemical remission, or histologic remission.
- 60 16. The method of any one of the preceding claims, wherein the anti-CD45 antibody is a chimeric antibody or a humanized antibody.
17. The method of any one of the preceding claims, wherein the anti-CD45 antibody is a human antibody.
- 65 18. The method of any one of the preceding claims, wherein the anti-CD45 antibody is intact.
- 70 19. The method of any one of the preceding claims, wherein the anti-CD45 antibody or antigen-binding portion thereof is selected from the group consisting of a monoclonal antibody or antigen-binding portion thereof, a polyclonal antibody or antigen-binding portion thereof, a bispecific antibody or antigen-binding portion thereof, a dual-variable immunoglobulin domain, a single-chain Fv molecule (scFv), a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a Fv fragment, a Fab fragment, a F(ab')₂ molecule, and a tandem di-scFv.
- 75 20. The method of any one of the preceding claims, wherein the anti-CD45 antibody has an isotype selected from the group consisting of IgG, IgA, IgM, IgD, and IgE.
21. The method of claim 20, wherein the anti-CD45 antibody contains a human IgG1, IgG2, IgG3, or IgG4 isotype Fc domain.

22. The method of any one of the preceding claims, wherein the anti-CD45 antibody, or antigen binding
80 portion thereof, comprises an Fc domain, and wherein the anti-CD45 antibody, or antigen binding portion
thereof, is conjugated to the cytotoxin by way of a cysteine residue in the Fc domain.

23. The method of claim 22, wherein the cysteine residue is introduced by way of an amino acid
substitution in the Fc domain.

24. The method of claim 23, wherein the amino acid substitution is D265C (EU numbering).


25. The method of any one of the preceding claims, wherein the cytotoxin is selected from the group
consisting of an pseudomonas exotoxin A, deBouganin, diphtheria toxin, saporin, maytansine, a
90 maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a
pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, and an
indolinobenzodiazepine dimer.

26. The method of any one of claims 1-24, wherein the cytotoxin is an auristatin; the cytotoxin is a
95 pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, an
indolinobenzodiazepine dimer, or an indolinobenzodiazepine pseudodimer; or the cytotoxin is an RNA
polymerase inhibitor.

27. The method of claim 26, wherein the auristatin is MMAE or MMAF.

28. The method of claim 26, wherein the RNA polymerase inhibitor is an amatoxin.

29. The method of claim 28, wherein the amatoxin is represented by formula (IA)



wherein R₁ is H, OH, OR_A, or OR_C;

110 substituted 5-membered heterocycloalkyl group;

110 substituted 5-membered heterocycloalkyl group;

R₃ is H, R_C, or R_D;

R₄, R₅, R₆, and R₇ are each independently H, OH, OR_C, OR_D, R_C, or R_D;

R₈ is OH, NH₂, OR_C, OR_D, NHR_C, or NR_CR_D;

R₉ is H, OH, OR_C, or OR_D;

115 X is -S-, -S(O)-, or -SO₂-;

R_C is $-L-Z$:

R_D is optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₂-C₆ alkynyl, optionally substituted C₂-C₆ heteroalkynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally


120 substituted aryl, or optionally substituted heteroaryl;


L is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₂-C₆ alkenylene, optionally substituted C₂-C₆ heteroalkenylene, optionally substituted C₂-C₆ alkynylene, optionally substituted C₂-C₆ heteroalkynylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, or a combination

125 thereof; and

Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within the antibody or antigen-binding fragment thereof, wherein Am comprises exactly one R_C substituent.


130 30. The method of any one of the preceding claims, wherein the anti-CD45 ADC has a formula of





, wherein Ab represents the anti-CD45 antibody.

or



, wherein Ab represents the anti-CD45 antibody.

145

- 150

155

160